Patents by Inventor Kelly Purpura

Kelly Purpura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20240052311
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 15, 2024
    Inventors: Yaling SHI, Erika MCAFEE, Samatha BANDAPALLE, Ann SIEHOFF, Timo GLEISSNER, Joseph O'CONNOR, Eytan ABRAHAM, Kelly PURPURA, Nuala TRAINOR, Timothy SMITH
  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20240018473
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 18, 2024
    Inventors: Yaling SHI, Erika MCAFEE, Samatha BANDAPALLE, Ann SIEHOFF, Timo GLEISSNER, Joseph O'CONNOR, Eytan ABRAHAM, Kelly PURPURA, Nuala TRAINOR, Timothy SMITH
  • End-to-end cell therapy automation
    Patent number: 11827902
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: November 28, 2023
    Assignees: LONZA WALKERSVILLE, INC., LONZA COLOGNE GMBH, OCTANE BIOTECH INC.
    Inventors: Yaling Shi, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith
  • End-to-end cell therapy automation
    Patent number: 11781113
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: October 10, 2023
    Assignees: LONZA WALKERSVILLE, INC., LONZA COLOGNE GMBH, OCTANE BIOTECH INC.
    Inventors: Yaling Shi, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith
  • End-to-end cell therapy automation
    Patent number: 11447745
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 20, 2022
    Assignees: LONZA WALKERSVILLE, INC., LONZA COLOGNE GMBH, OCTANE BIOTECH INC.
    Inventors: Yaling Shi, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith
  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20220282212
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 8, 2022
    Inventors: Yaling SHI, Erika MCAFEE, Samatha BANDAPALLE, Ann SIEHOFF, Timo GLEISSNER, Joseph O'CONNOR, Eytan ABRAHAM, Kelly PURPURA, Nuala TRAINOR, Timothy SMITH
  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20220282213
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 8, 2022
    Inventors: Yaling SHI, Erika MCAFEE, Samatha BANDAPALLE, Ann SIEHOFF, Timo GLEISSNER, Joseph O'CONNOR, Eytan ABRAHAM, Kelly PURPURA, Nuala TRAINOR, Timothy SMITH
  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20220282214
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 8, 2022
    Inventors: Yaling SHI, Erika MCAFEE, Samatha BANDAPALLE, Ann SIEHOFF, Timo GLEISSNER, Joseph O'CONNOR, Eytan ABRAHAM, Kelly PURPURA, Nuala TRAINOR, Timothy SMITH
  • End-to-end cell therapy automation
    Patent number: 11371018
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: June 28, 2022
    Assignees: OCTANE BIOTECH INC., LONZA WALKERSVILLE, INC., LONZA COLOGNE GMBH
    Inventors: Yaling Shi, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith
  • CELL CULTURE CHAMBER WITH IMPROVED CELL-CONTACTING SURFACES
    Publication number: 20210123008
    Abstract: The present disclosure provides cell culture chambers for use in automated cell engineering systems, and in particular, cell culture chambers that include improved cell-contacting surfaces. Improved cell-contacting surfaces can include a surface coating that promotes cell growth, adherence, differentiation, maintenance of phenotype, and/or improves transduction; a cell-contacting surface comprising a non-porous, gas-permeable material; as well as other modifications to the cell-contacting surfaces. Cassettes comprising the cell culture chambers are also provided.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 29, 2021
    Inventors: Nuala TRAINOR, Eytan ABRAHAM, Timothy SMITH, Matthew HEWITT, Yaling SHI, Kelly PURPURA, Chase MCROBIE
  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20200071670
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: October 30, 2019
    Publication date: March 5, 2020
    Inventors: Yaling SHI, Erika MCAFEE, Samatha BANDAPALLE, Ann SIEHOFF, Timo GLEISSNER, Joseph O'CONNOR, Eytan ABRAHAM, Kelly PURPURA, Nuala TRAINOR, Timothy SMITH
  • END-TO-END CELL THERAPY AUTOMATION
    Publication number: 20190169572
    Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
    Type: Application
    Filed: August 31, 2018
    Publication date: June 6, 2019
    Inventors: Yaling SHI, Erika McAfee, Samatha Bandapalle, Ann Siehoff, Timo Gleissner, Joseph O'Connor, Eytan Abraham, Kelly Purpura, Nuala Trainor, Timothy Smith